Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Bolis

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Nature Communications|December 3, 2021
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progressionMarco Bolis, Daniela Bossi, Arianna Vallerga, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Nature Communications|February 19, 2021
Patient-derived xenografts and organoids model therapy response in prostate cancerSofia Karkampouna, Federico La Manna, Andrej Benjak, et al.
Molecular Systems Biology|April 24, 2020
STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancerMonika Oberhuber, Matteo Pecoraro, Mate Rusz, et al.
Cancer Cell|March 3, 2023
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancerNicolò Bancaro, Bianca Calì, Martina Troiani, et al.
Nature Communications|February 3, 2021
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancerTiziano Bernasocchi, Geniver El Tekle, Marco Bolis, et al.
Nature Communications|July 30, 2025
Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibitionSiddhartha Mukherjee, Cindy Garda, Letizia Boffa, et al.
The Journal of Clinical Investigation|April 7, 2020
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivoAbdullah Alajati, Mariantonietta D'Ambrosio, Martina Troiani, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Nature Communications|December 3, 2021
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progressionMarco Bolis, Daniela Bossi, Arianna Vallerga, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Nature Communications|February 19, 2021
Patient-derived xenografts and organoids model therapy response in prostate cancerSofia Karkampouna, Federico La Manna, Andrej Benjak, et al.
Molecular Systems Biology|April 24, 2020
STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancerMonika Oberhuber, Matteo Pecoraro, Mate Rusz, et al.
Cancer Cell|March 3, 2023
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancerNicolò Bancaro, Bianca Calì, Martina Troiani, et al.
Nature Communications|February 3, 2021
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancerTiziano Bernasocchi, Geniver El Tekle, Marco Bolis, et al.
Nature Communications|July 30, 2025
Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibitionSiddhartha Mukherjee, Cindy Garda, Letizia Boffa, et al.
The Journal of Clinical Investigation|April 7, 2020
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivoAbdullah Alajati, Mariantonietta D'Ambrosio, Martina Troiani, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Pageof 8